Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Participants who submit written informed consent for study entry.~2. Participants aged greater than or equal to 20 and less than 85 years of age at the time of obtaining informed consent.~3. Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version or diagnosed with insomnia associated with psychiatric or physical disorder(s).~4. Participants with both of the following conditions which are persistent for 4 weeks or longer before the start of observation period:~   * Total sleep time is less than or equal to 390 minutes for more than or equal to 3 days a week~  * Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week~5. Participants with data at least 2 consecutive days in diary entries during observation period and confirmed to meet the following two criteria:~   * Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week~  * Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week~Exclusion criteria:~1. Participants with a present or history of the following disease specified in~   Mini-International Neuropsychiatric Interview (M.I.N.I.) Japanese version 5.0:~  * Risk of suicide~  * (Mild) manic episode~  * Post-traumatic stress disorder (PTSD)~  * Alcohol dependence and abuse~  * Drug (non-alcohol) dependence and abuse~  * Anorexia nervosa~  * Bulimia nervosa~  * Anti-social personality disorder~2. Participants with pharmacologically induced insomnia (drug-induced insomnia).~3. Participants with comorbid primary sleep disorders (circadian rhythm disorder, restless legs movement syndrome, periodic limb movement disorder, sleep apnea syndrome, etc.) other than primary insomnia.~4. Participants with symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturation, and cough.~5. Participants with unstable primary disease presenting insomnia during 4 weeks before the start of observation period.~6. Participants with organic mental disorder.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone 1 mg- Elderly (Type: EXPERIMENTAL): None
- Eszopiclone 2 mg- Elderly (Type: EXPERIMENTAL): None
- Eszopiclone 2 mg- Non-elderly (Type: EXPERIMENTAL): None
- Eszopiclone 3 mg- Non-elderly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).